GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Sirnaomics Unveils Robust Antitumor Efficacy of Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy

NextEdge Admin

13 Jun 2024

3 min 7 sec

Sirnaomics Ltd. a pioneering biopharmaceutical firm specializing in RNAi therapeutics, has unveiled a significant breakthrough with its innovative Oligonucleotide-Chemodrug Conjugate (ODC) agent. Published in the Journal of Oncology Research and Therapy (Volume 9, Issue 02), the research showcases the ODC's robust antitumor efficacy across various tumor cell lines and a pancreatic tumor model in mice. This advancement lays the groundwork for Sirnaomics' RNAi-based cancer therapeutic program, utilizing the proprietary Antibody-Oligonucleotide-Chemodrug Conjugate (AODC) approach.

Building upon previous research published in NAR Cancer (2020), the latest study enhances the ODC construct by incorporating chemically modified bases for improved stability and efficacy against CHK1 gene expression. In vitro assays demonstrate potent antitumor activity in pancreatic, NSCLC, TNBC, and ovarian cell culture models, with promising results against pancreatic tumors in mouse xenografts following intravenous administration using Sirnaomics' proprietary polypeptide nanoparticle formulation.

Dr. David Evans, Head of Discovery Research at Sirnaomics, emphasizes the potential of ODC constructs to enhance the potency and duration of small molecule therapeutics, mitigating drug resistance commonly encountered in cancer treatment. By targeting specific proteins associated with resistance mechanisms, AODCs offer a novel approach to overcoming chemodrug-induced resistance while minimizing systemic toxicity.

Founder, Chairman, and CEO Dr. Patrick Lu underscores the significance of this advancement in complementing Sirnaomics' ongoing clinical studies of STP705 for skin cancer, STP707 for solid tumors, and STP122G for anticoagulation therapy. The development of AODC agents presents an alternative strategy for treating various cancers, drawing upon the success of Antibody Drug Conjugates (ADCs) and fostering broad partnership opportunities.

One exemplary ODC, STP888, targets the CHK1 gene and incorporates gemcitabine to synergize with small molecule therapy. Through mRNA degradation and reduction of CHK1 protein levels, STP888 demonstrates enhanced efficacy while minimizing systemic toxicity. Sirnaomics aims to further optimize delivery by coupling STP888 with antibodies targeting tumor-specific markers, laying the foundation for Antibody Oligonucleotide-Drug Conjugates (AODCs) poised to revolutionize cancer therapy.